Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

DermaPure® saves 18 year old's leg from frost bite & is featured on US TV Programme

YORK, 1st June 2015 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, announces that DermaPure®, which is used in the treatment of chronic and acute wounds, has been featured in a US TV programme 'The Balancing Act®' highlighting its role in helping to save 18 year old Marty Smithson's leg from frostbite.

http://tissueregenixus.com/balancingact.html

During the programme Dr Marc Robins, specialist in Wound and Hyperbaric Medicine from Salt Lake City, Utah discusses recent medical advancements, including DermaPure®, to manage challenging cases from trauma wounds to treating diabetic foot ulcers. Diabetes affects 26 million people in the US and 25% of these will develop foot ulcers.

Antony Odell, CEO of Tissue Regenix, commented:

"This programme highlights the tremendous advance represented by DermaPure® and its capacity to heal many types of wounds, including old chronic wounds which are traditionally more challenging to treat. DermaPure has performed extremely well both in our study into acute wounds and across many other type of wounds arising from conditions such as traumatic injury, skin infections, and post-surgical deficits remaining after cancer removal. The efficacy of DermaPure® has been tested in some incredibly tough cases by clinicians across America and this particular case provides another example of why we have such confidence in our product."

ENDS

For Further Information

Tissue Regenix Group Plc: +44 19 0443 5176

Antony Odell

Ian Jefferson

Jefferies International Ltd: +44 20 7029 8000

Simon Hardy

Harry Nicholas

Tulchan Communications: +44 207 353 4200

Tom Buchanan

Victoria Huxster

Matt Low

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.